Source: Cyclo Therapeutics, Inc. 10/30/19
Trial Will Evaluate Safety and Efficacy of the Company’s Trappsol® Cyclo™ Drug in Alzheimer’s Disease
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology
company that develops cyclodextrin-based products for the treatment of
Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced
that it has signed an agreement with Worldwide Clinical Trials (Worldwide),
a leading Contract Research Organization (CRO), to conduct a clinical
trial to evaluate safety and efficacy in Alzheimer’s Disease. The trial
will evaluate Trappsol® Cyclo™ given by intravenous infusion.
The Company has previously reported encouraging data on safety and
efficacy of the product based on an FDA-approved expanded access program
in a single patient with late-onset Alzheimer’s Disease.
Alzheimer’s Disease affects 5.7 million Americans. While a few
symptomatic treatments are available, there are no approved disease
modifying treatments.
“We are very excited to work with Worldwide, an industry leader, on this
critical clinical program,” said N. Scott Fine, Company Chairman and
CEO. “Our work to advance an innovative approach to treat this
devastating disease may lead to improvements in the lives of Alzheimer’s
patients and their families. We are pleased to have Worldwide’s team of
experts working closely with us as we begin our development pathway.”
“The scientific, medical and operational experts at Worldwide offer
nearly 40 years of hard-won insight gleaned from our experience on the
front lines of Alzheimer’s Disease research. The journey toward halting
progression of this devastating neurodegenerative disorder takes
tenacity, and we’re not about to give up now,” said Henry Riordan,
executive vice president, Scientific Solutions, for Worldwide. “We are
thrilled to be selected by the innovators at Cyclo Therapeutics as their
partner in the development of this exciting new treatment approach.”
Cyclo Therapeutics and Worldwide are designing the trial protocol and
expect to schedule a scientific advice meeting with the U.S. FDA in
early 2020. Patient enrollment is expected to begin shortly thereafter.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that
develops cyclodextrin-based products for the treatment of disease. The
company’s Trappsol® Cyclo™, an orphan drug designated product
in the United States and Europe, is in three ongoing formal clinical
trials for Niemann-Pick Disease Type C, a rare and fatal genetic
disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
About Worldwide Clinical Trials:
Worldwide Clinical Trials employs more than 1,700 professionals around
the world, with offices in North and South America, Eastern and Western
Europe, Russia, and Asia. Founded by physicians committed to advancing
medical science, Worldwide is out to change how the world experiences
CROs – in the best possible way. From early phase and bioanalytical
sciences through late phase, post-approval and real-world evidence, we
provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute
predictable, successful studies with operational excellence across a
range of therapeutic areas, including central nervous system,
cardiovascular, metabolic, general medicine, oncology and rare diseases.
We never compromise on science or safety. We’re never satisfied with
the status quo. We’re the Cure for the Common CRO.
For more information, visit http://www.worldwide.com.
No comments:
Post a Comment